Aphiwe Dlokweni
Biographic Data
| ID | 8937371 |
|---|---|
| NAME | Aphiwe Dlokweni |
| GIVEN NAMES | Aphiwe |
| FAMILY NAME | Dlokweni |
| SIGNATURE | DLOKWENI A |
| AFFILIATIONS | University of KwaZulu-Natal |
| ORCID | 0000-0003-4235-2170 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Written on the Skin
To address challenges associated with the uptake of daily oral pre-exposure prophylaxis (PrEP) by young women at high risk of acquiring HIV, a range of novel, long-acting, slow-release products are being developed and clinically evaluated. One such technology is an annual implant of tenofovir alafenamide (TAF). This study explores the perspectives of participants from a first-in-human trial of an annual TAF implant to inform considerations for fu…
“There is nobody who wouldn’t like to”
A novel long-acting HIV oral pre-exposure prophylaxis (PrEP) implant was first tested in a Phase I clinical trial in South Africa, and this study sought to understand motivations behind trial participants enrolment, highlighting considerations for recruitment in future studies. Qualitative research was conducted using in-depth interviews (IDIs) with 29 study participants, 18 of whom also participated in focus group discussions (FGDs). Participant…
No prominent works on this page.
Written on the Skin
To address challenges associated with the uptake of daily oral pre-exposure prophylaxis (PrEP) by young women at high risk of acquiring HIV, a range of novel, long-acting, slow-release products are being developed and clinically evaluated. One such technology is an annual implant of tenofovir alafenamide (TAF). This study explores the perspectives of participants from a first-in-human trial of an annual TAF implant to inform considerations for fu…
“There is nobody who wouldn’t like to”
A novel long-acting HIV oral pre-exposure prophylaxis (PrEP) implant was first tested in a Phase I clinical trial in South Africa, and this study sought to understand motivations behind trial participants enrolment, highlighting considerations for recruitment in future studies. Qualitative research was conducted using in-depth interviews (IDIs) with 29 study participants, 18 of whom also participated in focus group discussions (FGDs). Participant…
Clinical trial (2 works) · HIV/AIDS Research and Interventions (2 works) · Human immunodeficiency virus (HIV) (2 works) · Public health (2 works) · Alternative medicine (1 work) · Contraceptive implant (1 work) · Ethics in Clinical Research (1 work) · Focus group (1 work) · HIV, Drug Use, Sexual Risk (1 work) · Implant (1 work)